دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
Amir Massarweh, MD, PhD, MHA1; Noa Eliakim-Raz, MD2,3,4; Amos Stemmer, MD4; Adva Levy-Barda, PhD5; Shlomit Yust-Katz, MD4,6; Alona Zer, MD1,4; Alexandra Benouaich-Amiel, MD1; Haim Ben-Zvi, PhD4,7; Neta Moskovits, PhD8; Baruch Brenner, MD1,4; Jihad Bishara, MD3,4; Dafna Yahav, MD3,4; Boaz Tadmor, MD9; Tal Zaks, MD, PhD10; Salomon M. Stemmer, MD1,4,8
doi : 10.1001/jamaoncol.2021.2155
JAMA Oncol. 2021;7(8):1133-1140
Do patients with cancer develop adequate antibody responses to messenger RNA SARS-CoV-2 vaccines?
Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan
Shu Yazaki, MD1,2; Tatsuya Yoshida, MD, PhD1,3; Yuki Kojima, MD, PhD2,4; Shigehiro Yagishita, MD, PhD4; Hiroko Nakahama, RN, MA5; Keiji Okinaka, MD6; Hiromichi Matsushita, MD, PhD7; Mika Shiotsuka, MD8; Osamu Kobayashi, MD, PhD8; Satoshi Iwata, MD, PhD8; Yoshitaka Narita, MD, PhD9; Akihiro Ohba, MD10; Masamichi Takahashi, MD, PhD9; Satoru Iwasa, MD, PhD1,11; Kenya Kobayashi, MD, PhD12; Yuichiro Ohe, MD, PhD3; Tomokazu Yoshida, PhD13; Akinobu Hamada, PhD4; Toshihiko Doi, MD, PhD14; Noboru Yamamoto, MD, PhD1
doi : 10.1001/jamaoncol.2021.2159
JAMA Oncol. 2021;7(8):1141-1148
Are there differences in seroprevalence and antibody levels for SARS-CoV-2 between patients with cancer and health care workers (HCWs) during the COVID-19 pandemic in Japan?
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment
Thomas W. P. Friedl, PhD1; Tanja Fehm, MD2; Volkmar Müller, MD3; Werner Lichtenegger, MD4; Jens Blohmer, MD5; Ralf Lorenz, MD6; Helmut Forstbauer, MD7; Visnja Fink, MD1; Inga Bekes, MD1; Jens Huober, MD1; Julia Jückstock, MD8; Andreas Schneeweiss, MD9; Hans Tesch, MD10; Sven Mahner, MD8; Sara Y. Brucker, MD11; Georg Heinrich, MD12; Lothar Häberle, PhD13; Peter A. Fasching, MD13; Matthias W. Beckmann, MD13; Robert E. Coleman, PhD14; Wolfgang Janni, MD1; Brigitte Rack, MD1
doi : 10.1001/jamaoncol.2021.1854
JAMA Oncol. 2021;7(8):1149-1157
Does extended adjuvant treatment with zoledronate for 5 years provide a survival benefit for patients with early breast cancer compared with 2 years of zoledronate treatment?
Estimated Performance of Transvaginal Ultrasonography for Evaluation of Postmenopausal Bleeding in a Simulated Cohort of Black and White Women in the US
Kemi M. Doll, MD, MS1,2; Sarah S. Romano, MPH3; Erica E. Marsh, MD4; Whitney R. Robinson, PhD5,6,7
doi : 10.1001/jamaoncol.2021.1700
JAMA Oncol. 2021;7(8):1158-1165
Do current guidelines that direct the use of transvaginal ultrasonography as a gateway to endometrial biopsy among women with postmenopausal bleeding perform differently by patient race?
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Michael A. Thompson, MD, PhD1; Jeffrey P. Henderson, MD, PhD2; Pankil K. Shah, MD, MSPH3; Samuel M. Rubinstein, MD4; Michael J. Joyner, MD5; Toni K. Choueiri, MD6; Daniel B. Flora, MD, PharmD7; Elizabeth A. Griffiths, MD8; Anthony P. Gulati, MD9; Clara Hwang, MD10; Vadim S. Koshkin, MD11; Esperanza B. Papadopoulos, MD12; Elizabeth V. Robilotti, MD, MPH12; Christopher T. Su, MD, MPH13; Elizabeth M. Wulff-Burchfield, MD14; Zhuoer Xie, MD, MS15; Peter Paul Yu, MD16; Sanjay Mishra, MS, PhD17; Jonathon W. Senefeld, PhD5; Dimpy P. Shah, MD, PhD18; Jeremy L. Warner, MD, MS19; for the COVID-19 and Cancer Consortium
doi : 10.1001/jamaoncol.2021.1799
JAMA Oncol. 2021;7(8):1167-1175
Is convalescent plasma therapy associated with improved outcomes of hospitalized patients with COVID-19 and hematologic cancer?
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy
Zhouguang Hui, MD1; Yu Men, MD1; Chen Hu, PhD2; Jingjing Kang, MD3,4; Xin Sun, MD3; Nan Bi, MD, PhD3; Zongmei Zhou, MD3; Jun Liang, MD3; Jima Lv, MD3; Qinfu Feng, MD3; Zefen Xiao, MD3; Dongfu Chen, MD3; Yan Wang, MD5; Junling Li, MD5; Jie Wang, MD5; Shugeng Gao, MD6; Luhua Wang, MD7; Jie He, MD6
doi : 10.1001/jamaoncol.2021.1910
JAMA Oncol. 2021;7(8):1178-1185
Can postoperative radiotherapy (PORT) using modern techniques improve survival of patients with pIIIA-N2 non–small cell lung cancer (NSCLC) after complete resection and adjuvant chemotherapy?
Association of Body Mass Index, Central Obesity, and Body Composition With Mortality Among Black Breast Cancer Survivors
Elisa V. Bandera, MD, PhD1,2,3; Bo Qin, PhD1,3; Yong Lin, PhD1,2; Nur Zeinomar, PhD, MPH1,3; Baichen Xu, MS1; Dhanya Chanumolu, MPH1,3; Adana A. M. Llanos, PhD, MPH1,2; Coral O. Omene, MD, PhD3; Karen S. Pawlish, ScD4; Christine B. Ambrosone, PhD5; Kitaw Demissie, MD, PhD6; Chi-Chen Hong, PhD5
doi : 10.1001/jamaoncol.2021.1499
JAMA Oncol. 2021;7(8):1186-1195
Are general and central obesity and body composition associated with mortality after diagnosis among Black breast cancer survivors?
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy
Betina Yanez, PhD1; Robert J. Gray, PhD2; Joseph A. Sparano, MD3; Ruth C. Carlos, MD4; Gelareh Sadigh, MD5; Sofia F. Garcia, PhD1; Ilana F. Gareen, PhD6; Timothy J. Whelan, MD7; George W. Sledge, MD8; David Cella, PhD1; Lynne I. Wagner, PhD9
doi : 10.1001/jamaoncol.2021.1693
JAMA Oncol. 2021;7(8):1196-1202
What risk factors are associated with early discontinuation of endocrine therapies among women with breast cancer in the Trial Assigning Individualized Options for Treatment?
Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers
Miranda P. Steenbeek, MD1; Marline G. Harmsen, MD, PhD1; Nicoline Hoogerbrugge, MD, PhD2; Marieke Arts de Jong, MD, PhD1; Angela H. E. M. Maas, MD, PhD3; Judith B. Prins, MD, PhD4; Johan Bulten, MD, PhD5; Steven Teerenstra, PhD6; Majke H. D. van Bommel, MD1; Helena C. van Doorn, MD, PhD7; Marian J. E. Mourits, MD, PhD8; Marc van Beurden, MD, PhD9; Ronald P. Zweemer, MD, PhD10; Katja N. Gaarenstroom, MD, PhD11; Brigitte F. M. Slangen, MD, PhD12; Monique M. A. Brood-van Zanten, MD13,14; M. Caroline Vos, MD, PhD15; Jurgen M. J. Piek, MD, PhD16; Luc R. C. W. van Lonkhuijzen, MD, PhD14; Mirjam J. A. Apperloo, MD17; Sjors F. P. J. Coppus, MD, PhD18; Leon F. A. G. Massuger, MD, PhD19; Joanna IntHout, PhD20; Rosella P. M. G. Hermens, PhD20; Joanne A. de Hullu, MD, PhD1
doi : 10.1001/jamaoncol.2021.1590
JAMA Oncol. 2021;7(8):1203-1212
What is the menopause-related quality of life in carriers of the BRCA1/2 pathogenic variant after salpingectomy with delayed oophorectomy compared with the standard salpingo-oophorectomy?
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia
Nitin Jain, MD1; Michael Keating, MD1; Philip Thompson, MD1; Alessandra Ferrajoli, MD1; Jan A. Burger, MD, PhD1; Gautam Borthakur, MD1; Koichi Takahashi, MD, PhD1; Zeev Estrov, MD1; Koji Sasaki, MD1; Nathan Fowler, MD2; Tapan Kadia, MD1; Marina Konopleva, MD, PhD1; Yesid Alvarado, MD1; Musa Yilmaz, MD1; Courtney DiNardo, MD1; Prithviraj Bose, MD1; Maro Ohanian, DO1; Naveen Pemmaraju, MD1; Elias Jabbour, MD1; Rashmi Kanagal-Shamanna, MD3; Keyur Patel, MD, PhD3; Wei Wang, MD, PhD3; Jeffrey Jorgensen, MD, PhD3; Sa A. Wang, MD3; Naveen Garg, MD4; Xuemei Wang, MS5; Chongjuan Wei, PhD1; Nichole Cruz, RN1; Ana Ayala, RN1; William Plunkett, PhD6; Hagop Kantarjian, MD1; Varsha Gandhi, PhD6; William G. Wierda, MD, PhD1
doi : 10.1001/jamaoncol.2021.1649
JAMA Oncol. 2021;7(8):1213-1219
What are the long-term responses with combined ibrutinib and venetoclax first-line therapy in patients with chronic lymphocytic leukemia?
Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease
Anders W. Erickson, BSc1,2; Steven Habbous, PhD2; Frances Wright, MD2,3; Aisha K. Lofters, MD, PhD2,4; Katarzyna J. Jerzak, MD5; Sunit Das, MD, PhD1,2,6
doi : 10.1001/jamaoncol.2021.1600
JAMA Oncol. 2021;7(8):1220-1224
What is the association of targeted therapy with survival for patients with intracranial metastatic disease (IMD)?
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Osama E. Rahma, MD1,2; Greg Yothers, PhD1,3; Theodore S. Hong, MD1,4; Marcia M. Russell, MD1,5,6; Y. Nancy You, MD7; William Parker, MS1,8; Samuel A. Jacobs, MD1; Linda H. Colangelo, MS1,3; Peter C. Lucas, MD, PhD1,9; Marc J. Gollub, MD10; William A. Hall, MD1,11; Lisa A. Kachnic, MD1,12,13; Namrata Vijayvergia, MD1,14; Mark A. O’Rourke, MD1,15; Bryan A. Faller, MD16; Richard K. Valicenti, MD17; Tracey E. Schefter, MD1,18; Katherine M. Moxley, MD1,19; Radhika Kainthla, MD20; Philip J. Stella, MD1,21; Elin Sigurdson, MD22; Norman Wolmark, MD1,23; Thomas J. George, MD1,24
doi : 10.1001/jamaoncol.2021.1683
JAMA Oncol. 2021;7(8):1225-1230
Does the addition of pembrolizumab to neoadjuvant chemoradiotherapy improve efficacy compared with chemoradiotherapy alone for patients with locally advanced rectal cancer who have completed neoadjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)?
Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging
Mehmet Emin Adin, MD1; Edvin Isufi, MD1; Michal Kulon, MD1; Darko Pucar, MD, PhD1
doi : 10.1001/jamaoncol.2021.1794
JAMA Oncol. 2021;7(8):1241-1242
Attitudes and Factors Associated With COVID-19 Vaccine Hesitancy Among Patients With Breast Cancer
Cynthia Villarreal-Garza, MD, DSc1,2; Bryan F. Vaca-Cartagena, MD1; Andrea Becerril-Gaitan, MD1; Ana S. Ferrigno, MD1; Fernanda Mesa-Chavez, MD1; Alejandra Platas, MSc2; Ana Platas, BA2
doi : 10.1001/jamaoncol.2021.1962
JAMA Oncol. 2021;7(8):1242-1244
Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer
Ruby M. van Stein, MD1; Arend G. J. Aalbers, MD2; Gabe S. Sonke, MD, PhD3; Willemien J. van Driel, MD, PhD4
doi : 10.1001/jamaoncol.2021.0580
JAMA Oncol. 2021;7(8):1231-1238
The peritoneal surface is a common site of disease in ovarian and colorectal cancer. Peritoneal metastases carry a poor prognosis, despite maximal therapeutic efforts, including surgical removal of tumor deposits and intravenous chemotherapy. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a single intraoperative procedure that delivers chemotherapy directly into the abdominal cavity, leading to high intracellular drug concentration at the peritoneal surface. This review describes the current knowledge regarding the mechanism of action, safety, and efficacy of HIPEC in the treatment of peritoneal metastases from epithelial ovarian and colorectal cancers and explores current knowledge gaps.
Sudden Paralysis in a 39-Year-Old Woman With Metastatic Breast Cancer
Claire Griffiths, MD1; Jennifer Connelly, MD2; Lubna N. Chaudhary, MD1
doi : 10.1001/jamaoncol.2021.1008
JAMA Oncol. 2021;7(8):1239-1240
Evaluating Cancer Drugs in Patients With Central Nervous System Metastases
Shanthi Marur, MD1; Julia A. Beaver, MD2; Richard Pazdur, MD2
doi : 10.1001/jamaoncol.2021.0180
JAMA Oncol. 2021;7(8):1111-1112
COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization
Eleni Korompoki, MD1; Maria Gavriatopoulou, MD1; Dimitrios P. Kontoyiannis, MD, ScD, PhD2
doi : 10.1001/jamaoncol.2021.1218
JAMA Oncol. 2021;7(8):1113-1114
The Need for Critical Examination of Disparities in Immunotherapy and Targeted Therapy Use Among Patients With Cancer
Sepideh Ashrafzadeh, BS1; Maryam M. Asgari, MD, MPH1,2; Alan C. Geller, RN, MPH3
doi : 10.1001/jamaoncol.2021.1322
JAMA Oncol. 2021;7(8):1115-1116
Equity and the JAMA Network
Phil B. Fontanarosa, MD, MBA1; Annette Flanagin, RN, MA2; John Z. Ayanian, MD, MPP3,4; Robert O. Bonow, MD, MS5,6; Neil M. Bressler, MD7,8; Dimitri Christakis, MD, MPH9,10; Mary L. Disis, MD11,12; S. Andrew Josephson, MD13,14; Melina R. Kibbe, MD15,16; Dost Öngür, MD, PhD17,18; Jay F. Piccirillo, MD19,20; Rita F. Redberg, MD, MPH21,22; Frederick P. Rivara, MD, MPH23,24; Kanade Shinkai, MD, PhD25,26; Clyde W. Yancy, MD, MSc27,28
doi : 10.1001/jamaoncol.2021.2927
JAMA Oncol. 2021;7(8):1119-1121
Adjuvant Zoledronate Therapy for Women With Breast Cancer—Effective Treatment or Fool’s Gold?
Alexandra Desnoyers, MD1; Eitan Amir, MBChB, PhD1; Ian F. Tannock, MD, PhD1
doi : 10.1001/jamaoncol.2021.1516
JAMA Oncol. 2021;7(8):1121-1123
Immune Responses to SARS-CoV-2 Among Patients With Cancer
Lova Sun, MD1; Jeremy L. Warner, MD, MS2,3; Ravi B. Parikh, MD, MPP1,4
doi : 10.1001/jamaoncol.2021.2096
JAMA Oncol. 2021;7(8):1123-1125
A Race-Conscious Analysis of the Use of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding
Eloise Chapman-Davis, MD1; Dineo Khabele, MD2
doi : 10.1001/jamaoncol.2021.1681
JAMA Oncol. 2021;7(8):1165-1166
Time-Related Biases in Nonrandomized COVID-19–Era Studies Using Real-world Data
Gregory S. Calip, PharmD, MPH, PhD1,2; Rebecca A. Miksad, MD, MPH1,3; Somnath Sarkar, PhD1
doi : 10.1001/jamaoncol.2021.1715
JAMA Oncol. 2021;7(8):1175-1177
Leaning Into Uncertainty and Discomfort With Hope
Evelyn Anthony, MD1; Katherine Files, MBA2; Suzanne C. Danhauer, PhD3
doi : 10.1001/jamaoncol.2021.1496
JAMA Oncol. 2021;7(8):1117-1118
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker
Longgang Cui, PhD1; Fan Zhang, MD2
doi : 10.1001/jamaoncol.2021.1867
JAMA Oncol. 2021;7(8):1244-1245
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker—Reply
Cristina Valero, MD, PhD1; Timothy A. Chan, MD, PhD2,3; Luc G. T. Morris, MD, MSc1
doi : 10.1001/jamaoncol.2021.1870
JAMA Oncol. 2021;7(8):1245-1246
Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
Catherine Dunn, MBBS1; Lucy Gately, MBBS, PhD1; Peter Gibbs, MBBS, MD1,2
doi : 10.1001/jamaoncol.2021.1904
JAMA Oncol. 2021;7(8):1246
Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?—Reply
Erin F. Cobain, MD1; Arul M. Chinnaiyan, MD, PhD2,3,4,5,6
doi : 10.1001/jamaoncol.2021.1907
JAMA Oncol. 2021;7(8):1246-1247
Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer
Samilia Obeng-Gyasi, MD, MPH1; Ruth C. Carlos, MD2
doi : 10.1001/jamaoncol.2021.1953
JAMA Oncol. 2021;7(8):1247-1248
Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer
Junyu Long, PhD1; Xinting Sang, PhD1; Haitao Zhao, MD1
doi : 10.1001/jamaoncol.2021.1956
JAMA Oncol. 2021;7(8):1248
Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer—Reply
Kent F. Hoskins, MD1; Gregory S. Calip, PharmD, MPH, PhD2
doi : 10.1001/jamaoncol.2021.1959
JAMA Oncol. 2021;7(8):1248-1249
